California has opened a new human stem cell collection that officials say will enable new disease investigations and could result in exciting drug discoveries. Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) praised the opening and looks forward to the outcome of the future stem cell therapy studies, leaving open the possibility of taking part in some of them. Hosted and funded by the California Institute for Regenerative Medicine, the Stem Cell Bank in Novato will have 300 stem cell lines available immediately and will expand to 750 lines by February 2016. The repository will enable scientists to examine stem cells representing autism, epilepsy and other childhood neurological disorders; blinding eye diseases; heart, lung and liver diseases; Alzheimer's disease, and relevant control samples. "Stem cell therapy research holds great promise for finding effective treatments and cures for many diseases," said RBCC CEO Kimberly Palmer. "This is a quantum step forward for the entire medical community, particularly for regenerative medicine and biomedicine, two of our core businesses. We've been active in searching out partnerships to participate in and to take advantage of breakthroughs such as this and will continue to do so. The potential for drugs and treatments resulting from adult stem cell research is unlimited, both in terms of marketing, and more importantly, for the good of the human race." Noted analysts Frost and Sullivan predict the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030. RBCC is dedicated to delivering advanced medical research and technologies to a booming global health marketplace. For more information on RBCC's initiatives, please visit www.rainbowbiosciences.com. About Rainbow Biosciences Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. ( RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.